Kyntra Bio (KYNB) Return on Capital Employed (2015 - 2026)
Kyntra Bio (KYNB) posted Return on Capital Employed of 51.79% for Q1 2026, down 11.78% sequentially from 46.33% in Q4 2025, and up 4793.0% YoY from 1.06% in Q1 2025.
Kyntra Bio (KYNB) Return on Capital Employed (2015 - 2026) Analysis & Trends
Kyntra Bio has reported Return on Capital Employed for 12 years, with the latest figure at 51.79% in Q1 2026.
- Quarterly Return on Capital Employed rose 4793.0% year-over-year to 51.79% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 51.79% (up 4793.0% YoY) and the FY2025 annual result came in at 33.3%, up 4769.0% from the prior year.
- Return on Capital Employed fell to 51.79% in Q1 2026 per KYNB's latest filing, from 46.33% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 32.51% in Q3 2025 and troughed at 519.71% in Q2 2025.
- A 5-year average of 128.41% and a median of 98.3% in 2023 frame the typical range for Return on Capital Employed.
- The widest YoY moves for Return on Capital Employed: up 23752 bps in 2025, down 37924 bps in 2025.
- Over 5 years, Return on Capital Employed stood at 89.62% in 2022, then sank by 61 bps to 143.87% in 2023, then advanced by 2 bps to 141.68% in 2024, then surged by 67 bps to 46.33% in 2025, then dropped by 12 bps to 51.79% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 51.79%, 46.33%, and 32.51% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 26.09% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -50.93% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 7.88% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -6.85% |
| 10 | Kyntra Bio | 29.83 Mn | 29.83 Mn | 1.47 Mn | -72.59% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -72.59% |
| Mar 31, 2026 | -51.79% |
| Dec 31, 2025 | -46.33% |
| Sep 30, 2025 | -32.51% |
| Jun 30, 2025 | -519.71% |
| Mar 31, 2025 | -99.72% |
| Dec 31, 2024 | -141.68% |
| Sep 30, 2024 | -270.02% |
| Jun 30, 2024 | -140.47% |
| Mar 31, 2024 | -149.43% |
| Dec 31, 2023 | -143.87% |
| Sep 30, 2023 | -105.54% |
| Jun 30, 2023 | -97.35% |
| Mar 31, 2023 | -98.30% |
| Dec 31, 2022 | -89.62% |
| Sep 30, 2022 | -93.51% |
| Jun 30, 2022 | -47.37% |
| Mar 31, 2022 | -55.72% |
| Dec 31, 2021 | -49.18% |
| Sep 30, 2021 | -34.06% |